30 Jun Prodesse enters patent agreement with Roche
Waukesha, Wis. – Prodesse Inc., a biotechnology company focused on the development and distribution of reagents for the testing of infectious diseases, has entered into an in-vitro diagnostics patent license agreement with Roche, the Basel, Switzerland-based pharmaceutical firm.
Under the agreement, which will be effective July 1, Prodesse receives the right to include Roche enzymes in its products. Prodesse also receives the authority to convey end-user rights, under Roche patents, to its customers with sale of products for the influenza A virus, influenza B virus, and other viruses.
• Prodesse gets new funding; improves flu assay
• Teresa Esser: Entrepreneurial Profile: Kelly Henrickson, founder of Prodesse, Inc.